STAREE Trial: Atorvastatin Lowers Major Cardiovascular Events in Healthy Older Adults, No Impact on Disability-Free Survival

Findings from the STAREE trial, presented at ESC Congress 2026 and simultaneously published in the New England Journal of Medicine, indicate that treatment with atorvastatin led to a 30% relative reduction in major cardiovascular events over approximately six years compared to placebo in community-dwelling older adults. The trial involved nearly 5,000 adults over 70 with no history of cardiovascular disease, diabetes, or dementia. However, the study found no significant difference in disability-free survival between the atorvastatin and placebo groups.